Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) was featured in CTV News' W5 program, which aired Part Three of an investigative series examining the company's allegations of stock spoofing tied to its USD $700 million lawsuit against CIBC and RBC. The episodes detail rising market-manipulation cases in Canada and highlight Quantum's call for accountability. CEO Zeeshan Saeed reaffirmed the company's commitment to defending shareholders and advancing MS research through its lead compound, Lucid-MS, a patented new chemical entity shown to prevent and reverse myelin degradation in preclinical models. Co-Executive Chair Anthony Durkacz has offered up to USD $7 million for information leading to a final judgment or settlement in related litigation.
Quantum BioPharma is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., the company focuses on the research and development of Lucid-MS, targeting the underlying mechanism of multiple sclerosis. The company also invented unbuzzd(TM) and spun out its OTC version to Unbuzzd Wellness Inc., retaining ownership of 20.11% of the company as of March 31, 2025.
The agreement includes royalty payments of 7% of sales from unbuzzd(TM) until payments to Quantum BioPharma total $250 million, after which the royalty drops to 3% in perpetuity. Quantum BioPharma retains 100% of the rights to develop similar products for pharmaceutical and medical uses. Additional information about the company is available in its newsroom at https://ibn.fm/QNTM. The press release containing this information was disseminated through InvestorWire, a specialized communications platform that is one of 70+ brands within the Dynamic Brand Portfolio at IBN, providing wire-grade press release syndication and corporate communications solutions. Full terms of use and disclaimers are available on the InvestorWire website at https://www.InvestorWire.com/Disclaimer.
This development matters because it brings significant attention to alleged market manipulation practices affecting publicly traded companies, particularly in the biopharmaceutical sector where research funding and investor confidence are crucial. The $700 million lawsuit against major Canadian financial institutions represents one of the largest such cases, potentially setting precedents for how stock spoofing allegations are handled in Canadian markets. Meanwhile, the company's focus on Lucid-MS addresses a critical medical need, as multiple sclerosis affects approximately 2.8 million people globally with limited disease-modifying treatments available.
The financial implications extend beyond the lawsuit, as the company's business model includes strategic partnerships like the unbuzzd(TM) arrangement that provides ongoing revenue streams while maintaining pharmaceutical development rights. The $7 million reward offered for information demonstrates the company's serious approach to resolving the litigation, which could significantly impact shareholder value depending on the outcome. These events collectively highlight the intersection of financial market integrity and medical innovation, where allegations of market manipulation could potentially undermine investor confidence in companies developing important therapies for serious neurological conditions.
